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lubir domain of the IL-4Ra dudn completely abelhh the binding 
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receptor tflllgeflng, IL-13 and IL.4 Induce the phosphorytation 
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rmdta In Its tight association with phosphatidylinodtol-3-klnase. 
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!. In~'ndeetlea 
Intedeukin-13 (IL-13) is a cytokine secreted by activated 
T lymphocytes which regulates inflammatory and immune re- 
sponges [!,2]. It shares several biological activities with IL-4, 
another T-cell derived cytokine, in a variety of cell types such 
as B cells, monocytes, fibroblasts and endothelial cells [3]. The 
functional redundancy of I L4  and 11,-13 could result from the 
utilization of the same receptor complex, but the differences 
observed between the biological effects of these cytokines on, 
for example, T cells, suggested an overlapping but not identical 
population of receptors, in fact, Zurawski et al. [4] recently 
showed that the receptors for IL-4 and IL-13 are structurally 
related. Furthermore, it has been shown that a mutated I L4  
[5] that blocks the biological activity of I L4  also antagonises 
IL.13 activity [4,6], adding support for a shared component(s) 
important for signal transduction between both receptors. TWo 
proteins have been described as components ofthe high affinity 
I L4  receptor, a giycoprotein of -130 kDa (IL-4Ra) [7,8] that 
when expressed in COS-7 cells binds IL-4 with a /~ of 50-100 
pM [4], and the T chain of the 11.-2 receptor (Y~) [9,10] that when 
associated to the ILAR results in a 2-3-fold increase in affinity 
for I L4  [9] and also participates in some of the IL-4 mediated 
dgnal transduction events [10]. ~ recently showed that neither 
of these two chains was responsible for the binding cross.com- 
petition of IL.4 and tl.-13, and we proposed that the IL-13 
t~'~eptor may be constituted by the IL.4 receptor complex asso. 
dated with another component, probably a protein of 55-70 
k~ [ill, 
Here we describe the characterization of the recepto's for 
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IL-13 and IL-4 and signal transduction events triggered by 
these cytokines in the human premyeloid erythroleukemia cell 
line TF-I, a cell line that proliferates in response to both pro- 
teins. Taken together, our results how that the IL-13 binding 
site is closely associated with the IL-4R¢ chain which, by itself, 
does not bind 11,-13; and that following receptor triggering 
both cytokines elicit the phosphorylation f a 170 kDa protein, 
probably the IL-4-induced phosphotyrosine substrate (4PS), 
and the association of this protein with phosphatidylinositol-3. 
kinase (Pl-3K). 
2. Materials and methods 
Z 1. Growth factors, mltibodies and cells 
Recombinant IL-I 3 was produced and purified in our laboratory as 
previously described [1], human IL-4 was obtained from Tebu (Le 
Perray en Yvelines, France) and GM-CSF from Genzyme (Cambridge, 
MA). The anti-phosphotyrosine (P-Tyr) antibody, the agarose conju- 
gated 4(310 anti-P-Tyr, the anti-rat Pl-3K (p85), the anti-mouse JAK-I, 
JAK-2 and JAK-3 were from UBI (Lake Placid, NY). The anti-rabbit 
IgG and anti-mouse 18(3 peroxidase conjugates were purebased from 
Sigma (St. Louis, MO) and the protein G-plus/protein A-Agarose from 
Oncogene Sdence (Uniondale, NY). The anti-IL-4 receptor antibodies 
X2/45 and $456C9 were provided by Dr. Sebald 0Viirzburg) or pur- 
chased from lmmunotech (Marseille, France). 
TF-I cells, kindly provided by Dr. P. Manoni (Marseille, France), 
were cultured in RPMI 1640, 10% fetal calf serum (FCS), 2 mM glutam- 
ine, penicillin/streptamycin (100 unitshrd) and l ng/ml GM-CSF, at 
370C in a humidified atmosphere containing 5% CO2. 
2,2, Cell proliferation and binding assay 
TF-I cells were washed twice with GM-CSF-detqeted medium and 
incubated with appropriate amounts of IL-4 or IL-13 for 72 h. To test 
the inhibition of proliferation, the cells were preincubated for 1 h at 
37eC with appropriate amounts of anti-IL-4 receptor antibodies. The 
biological activity was measured by an in vitro colorimetric assay pre- 
viously described [12]. 
Binding experiments were carried out as described [1 I] with '2sI- 
[F~]IL-13-GYGY (360 pM) as labeled ligand. For the inhibition of 
binding, the cells were incubated for ! h at 37°C with the appropriate 
amounts of the different antibodies. 
2.3. K~stcrv bla;tt~g& 
TF-I cells were washed twice in RPMI 1640 containing 2mM 81u- 
tamine (starvation medium) and incubated overnight in the same me- 
dium at 37°C. The cells were collected, resuspended at l06 cells/ml in 
starvation medium containing 50 #M Na3VO4, and stimulated with 
either IL-4, IL-13 or GM-CSF for 10 gin at 37°C. The cells were 
washed at 4°C with 10 mM Tris-HCI, pH 7.4, 150 mM NaCI (TBS) 
containing 100 pM Na3VO4, pelleted and lysed in 25 mM Tris-HCl, pH 
7.5, 150 mM NaCI, I% NIM0, 1 mM EDTA, 1 mM Na3VO4, 50 mM 
NaF, ! mM phenylmethylsulfonyl fluoride, I /zg/ml leupeptin and 
I pg/ml pepstatin (iysis buffer). Cell lysates were cleared by centrifuga. 
tion for 15 min at 15,000 xg, analyzed in 7.5% SDS-PAGE and trans- 
ferred to nitrocellulose membranes (BioRad, Richmond, CA). The 
membranes were blocked with TBS containing 6% BSA, and probed 
with antibodies in TBS containing 0.1% Tween 20 and 0.5% BSA for 
1-2 h and visualised by an ECL system (Amersham Corp., Bucking- 
hamshire, UK). 
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2,4. lmmunoprecipitation 
Proteins (1 mg) were immunoprecipitated from clarified cell lysates 
by addition of 70/zl agarose conjugated 4GI0 anti P-Tyr or with 5/zl 
of other antisera plus 50/zl of protein GIA-Agarose and incubated 
overnight at 4°C. The immunoprecipitates were washed three times 
with lysis buffer, solubilized with Laemmli buffer and analyzed on 7.5% 
SDS-PAGB. Western blotting was carried out as described above. 
3. R ~  
3.1. Monoclonal antibodies anti IL-4 receptor inhibit 1L-13 
binding to TF-1 cells 
Both IL-13 and IL-4 are growth factors for the premyeloid 
erythroleukemia cell line TF-I. In these cells the binding of 
iodinated IL-13 is fully displaced by IL-4 (Fig. IA) but the 
binding of IL-4 is only partially displaced by IL-13 [11]. The 
Scatchard plot generated from saturation experiments carried 
out with labeled IL-13 and IL-4 showed that the number of 
binding sites for IL-13 is half of that ~'or IL.,,t (data not shown 
and [11]) suggesting that not all of th~ IL-4 binding sites are 
shared by IL-13, The high affinity IL-13 binding (K,, 330 + 20 
pM) was displaced by two monoclon,~l antibodies, X2145 and 
$456C9, raised against he extracellular domain of the IL-4Ra 
chain, As shown in Fig. 1 B, both antibodies are able to fully 
compete with labeled IL-I ~. on TF-I cells with ICs0 of 4 + ! nM 
and 2 + 0.5 nM, respectively, Similar displacement were ob- 
tained when iodinated IL-4 was used as labeled ligand in bind- 
ing experiments (data not shown). 
These results are in agreement with the observation that 
these antibodies inhibited the IL-I 3 and IL-4 induced prolifer- 
ation of TF-I cells at concentrations similar to those necessary 
to inhibit the binding (Fig. IC). 
3.2. IL-13 and IL-4 induce similar tyrosine phosphorylation 
patterns in TF.I cells 
Since IL-13 receptors overlap with those for IL-4 in TF-I 
cells we decided to investigate whether these cytokines had 
similar effects on the events following receptor triggering. We 
analyzed protein tyrosine phosphorylation after stimulation by 
IL-4 and IL-13. The phosphorylation i duced by GM.CSF, a 
well-known growth factor for these cells, was also investigated. 
The cells, washed and deprived of GM-CSF and FCS over- 
night, were stimulated with IL-4 or IL-13 (100 ng/ml), or with 
GM-CSF (2 ng/ml). Tyrosine phosphorylation was analyzed as 
described in section 2. As shown in Fig. 2, IL-4 and IL-13 
induced a prominent yrosine-phosphorylated band of 170 
kDa. GM-CSF stimulation resulted in a different pattern of 
phosphoproteins, three bands of 97, 80 and 60 kDa were ob- 
served, whereas no protein corresponding in size to the 
phosphorylated 170 kDa band induced by IL-13 and IL-4 was 
detected. Weak phosphorylation of an 80 kDa protein was 
observed in some experiments in response to IL-4 and IL-13. 
The 170 kDa protein was tyrosine-phosphorylated in a dose- 
dependent manner by IL-13 (Fig. 3A). Weak tyrosine phospho- 
rylation of the 170 kDa was observed in response to a low 
concentration f IL- 13 (0.028 nM), and was maximal at 2.8 nM. 
Similar results were observed with IL-4 (Fig. 3B). The protein 
tyrosine phosphorylation induced by IL-13 was in a dose range 
similar to that necessary to induce proliferation, suggesting that 
the phosphorylation may correlate with IL-13-dependent 
growth signal transduction. 
The tyrosine phosphorylation of the 170 kDa protein 
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Fig. 1. IL.13 binding and growth promoting activity inhibition by 
antibodies anti-IL-4R~ chain, (A) Competitive displacement of ~2sl- 
[F4,~]-IL-I 3-GYGY binding by IL-I 3 (4) and IL-4 (a), (B) Competitive 
displacement of I~I-[F43]-IL-13-GYGY binding by monoclonal anti- 
bodies 5456C9 (O) and X2145 (o), raised against he extracellular do- 
main of the [L-4R~ chain. Each point represents the mean of triplicates. 
(C) IL-13 (0.5 #g/ml) growth promoting activity in the absence (D) and 
in the presence of monoclonal ntibodies $456C9, 16/zg/ml, (e), and 
X2/45, 10gg/ml (o), and 20/~g/ml (B). Each point represents he mean 
of triplicates. 
induced by IL-13 was rapid. Two rain aftel" stimulation the 
phosphorylation was already maximal, the effect remained sta- 
ble for 30 rain and decreased after 2 h (Fig. 3C). 
The phosphorylation of Janus kinases in the different sam- 
ples was analyzed by blotting with anti P-Tyr either directly, 
or after immunoprecipitation with anti JAK-I and JAK-3 anti- 
bodies. Both techniques failed to reveal IL-! 3- or IL-4-induced 
phosphorylation f these kinases (data not shown). 
3.3. IL.13 induced phosphorylation of the 170 kDa protein 
results in its association with PI-3K in TF-I cell~" 
PI-3K has been shown to associate, through the 4PS, with 
the IL-4 receptor complex in response to IL-4 [13]. Since we 
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Fig. 2. Protein tyrosine phosphorylation n TF-! cells. The cells were 
starved and stimulated with cytokines as described insection 2. Cell 
lysates were separated by SDS-PAGE, transferred to nitrocellulose 
membranes, and immunoblotted with anti-P-Tyr antibodies. 
observed the same tyrosine phosphorylation pattern induced by 
IL-13 or IL-4, we investigated whether the IL-13 also induces 
the assodation of Pl-3K to the receptor complex. Fig. 4A 
shows the detection of the 170 kDa protein phosphorylated in 
respon~ to IL-13 and IL4 as detected with antibodies anti 
P-T~r on whole cell lysates, When the samples were first im- 
munopre¢ipitated with an antibody c;irected against the 85 kDa 
subunit of Pl-3K and subsequently immunoblotted with anti 
P-Tyr antibodies, the phosphorylated 170 kDa protein was also 
dearly detected (Fig, 4B). if the same santples were im- 
munoblotted with antibodies directed against he 25 kDa sub- 
unit of PI-3K, this protein was observed at the expected posi- 
tion in the gel (Fig. 4(3). These results how that the 170 kDa 
protein associates with the PI-3K after receptor triggering by 
!1-13 and IL4, They also show that neither 11,-13 nor IL4 
stimulates the phosphorylation fthe 85 kDa subunit of Pl-3K. 
GM-CSF-treated lysates immunopre¢ipitated with anti-p85 
serum and immunoblotted with anti P-Tyr did not show any 
specific phosphorylated protein. 
The purpose of this study was to characterize the receptors 
for !1,-13 and IL4 and the signal transduction events trigger 
by both cytokines in the premyeloid erythroleukemia cell line 
TF-I. These cells are dependent on GM-CSF but they can 
proliferate in response to !I.,-13 and IL-4 and thus provide an 
interesting model for the study of the IL-41IL-13 receptor sys- 
tem. We recently proposed that the IL-I 3 receptor consist of 
the IL-4 receptor complex associated with at least one addi- 
tional protein [11]. We show here that, in line with this model, 
two monoclonal ntibodies against the extracellular domain of 
the IL-4Ra chain completely abolish the binding of labeled 
IL-13. The IL-4Ra chain by itself does not bind IL-13 [4,11], 
thus the inhibition of the binding by these two antibodies is 
probably due to steric competition and suggests a close associ- 
ation of the IL-13 binding molecule with the IL-4Ra. 
Our results also show that, in TF-1 cells, both IL-13 and IL-4 
induce rapid tyrosine phosphorylation f a 170 kDa protein. 
This protein is most probably 4PS previously described [13]. 
4PS is a protein functionally and structurally related to IRS-I 
[14], which following insulin interaction with its receptor, is 
phosphorylated and associates with signaling molecules pre- 
senting the SH-2 (Src homology) domain (for review see [15]). 
The IL-4 induced phosphorylation f 4PS results in its associa- 
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Fig. 3. Protein tyrosine phosphorylation n TF-I cells. (A) IL-13 and 
(B) IL-4 dose dependent tyrosine phosphorylation. (C)Time course 
phosphorylation following IL-13 treatment. Cells were lysed and 
phosphoproteins a alyzed as in Fig. 2. 
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Fig. 4. Association of the phosphorylated 170 kDa/4PS protein with PI-3K in TF-I cells. (A) Protein tyrosine phosphorylation n cell lysates 
immunoblotted with anti-P-Tyr antibodies. (B) Protein tyrosine phosphorylation n cell lysates immunoprecipitated with anti-PI-3K antibodies and 
immunoblotted with anti-P-Tyr antibodies. (C) Cell lysates immunoblotted with anti-PI-3K antibodies. Samples were separated by SDS-PAGE, 
transferred tonitrocellulose membranes, and immunoblotted as described insection 2. 
tion with, among other proteins, the p85 subunit of PI-3K, 
thereby inducing PI-3K activity [13]. Our results how that in 
TF-I cells, IL-13, as well as IL-4 activation, results in the 
association of PI-3K to the phosphorylated 170 kDa protein. 
The response of the TF-I cells to GM-CSF, which also pro- 
motes proliferation of these cells, was clearly different, since 
among several proteins that were phosphorylated the 170 kDa 
one was absent. Thus, these results upport he hypothesis of 
common signal transduction proteins for the IL-I 3/IL-4 recep- 
tor complex and are in line with the observation that both 
cytokines activate the same recently identified transcription 
factor NF-IL-4 which binds to the specific responsive lement 
IL-4RE [16]. 
We failed to observe the previously described phosphoryla- 
tion [13,17] of the IL-4R0~ chain by either IL-13 or IL-4 by 
Western blot with the anti.P-Tyr antibody on total TF-I lysates 
and on IL-4R~ immunoprecipitates, probably because of the 
low number of receptors. However, phosphorylation of this 
chain appears to be a pre-requisite for phosphorylation f the 
170 kDa protein [13]. It should also be noted that under our 
conditions we did not see phosphorylation f the Janus kinases 
JAK-I and JAK-3 following receptor triggering by IL-13 or 
IL-4. IL-4-induced JAK-I and JAK-3 phosphorylation has 
been described in natural killer and T cells [18,19]. Interestingly, 
some Janus kinases are associated to the receptor through the 
IL-2 receptor 7c, but the participation of the 7c may be cell 
dependent, because recently it has been shown that in X-linked 
severe combined immunodeficient B cells, in which the 7c gene 
is disrupted, the response to IL-4 and IL-13 is not impaired [20]. 
Further work is in progress to assess whether this observation 
is associated with the number of receptors or with the type of 
receptor complex present in TF-I cells. 
In summary, our results how that the IL-13 binding site is 
closely associated to the IL-4R0~ chain which, by itself, does not 
bind IL-13; and that both cytokines elicit similar intracellular 
events following receptor triggering. These findings are in line 
with the hypothesis that the IL-13 receptor may constitute a
subset of iL-4 receptors containing the IL-4 binding subunit 
associated with at least one additional protein. 
Acknowledgements: We thank Dr. W. Sebald for the monoclonal nti- 
body, anti-IL-4R0t chain, Dr. P. Manoni for the TF-! cells, and Dr. D. 
Shire, A. Minty and J.C. Guillemot for critical reading of the manu- 
script and stimulating suggestions and discussions. 
References 
[1] Minty, A., Chalon, P., Derocq, J.M., Dumont, X., Guillemot, J.C., 
Kaghad, M., Labit, C., Leplatois, P., Liauzun, P., Miloux, B., 
Minty, C., Casellas, P., Loison, G., Lupker, J., Shire, D., Ferrara, 
P. and Caput, D. (1993) Nature 362, 248-250. 
[2] McKenzie, A.N., Culpepper, J.A., de Waal Malefyt, R., Briere, F., 
Punnonen, J., Aversa, G., Sato, A., Dang, W., Cocks, B.G., 
Menon, S., de Vries, J.E., Banchereau J. and Zurawski, G. (1993) 
Proc. Natl. Acad. Sci. USA 90, 3735-3739. 
[3] Zurawski, G and de Vries, J.E. (1994) lmmunol. Today 15, 19-26. 
[4] Zurawski, S.M., Vega Jr., F., Huyghe, B. and Zurawski, G. (1993) 
EMBO J. 12, 2663-2670. 
[5] Kruse, N., Tony, H.P. and Sebald, W. (1992) EMBO .~ i 1, 3237- 
3244. 
[6] Aversa, G., Punnonen, J. Cocks, B.G., de Waal Malefyt, R., Vega 
Jr., E, Zurawski S.M., Zurawski, G. and de Vries, J.E. (1993) 
J. Exp. Med. 178, 2213--2218. 
[7] ldzerda, R.L., March, C.J., Mosley, B., Lyman, S.D., Vanden Bos, 
T., GimpeI,S.D., Din, W.S., Grabstein, K, Widmer, M.B., Park, 
L.S., Cosman, D. and Backmann, M.P. (1990) J. Exp. Med. 171, 
861-873. 
126 S. Lefort et al. / FEBS Letters 366 (1995) 122-126 
[8] Galizzi, J.P., Zuber, C.E., Harada, N., Gorman, D.M., Djossou, 
O., Kastelein, R., Banchereath J., Howard, M. and Miyajima, A. 
(1990) Int. lmmtlnol. 2, 669-675. 
[9] Kondo M., Takeshita, 3"., Ishii, N., Nakamura, M., Watanabe, S., 
Arai K. and Sugamara K. (1993) Science 262, 1874-1877. 
[10] R~sell, S.M,, Keegan, A.D, Harada, N., Nakamara, Y., 
Noguchi, M., Leland, E, Friedmann, M.C., Miyajima, A., Puri, 
R.K., Paul, W.E. and Leonard, WJ. (1993) Science 262, 1880- 
1883. 
[!!] Vita, N., Lefort, S., Laurent, P., Caput, D. and Ferrara, P. (1995) 
J. Biol. Chem. 270, 3512-3517. 
[12] Labit-LebouteiUer, C., Astruc, R., Minty, A, Ferrara, E and Lup- 
ker J. (1995) J. Immunol. Methods (in press). 
[13] Wang, L.M., Keegan, A.D., Paul, W.E., Heidaran, M.A., 
Gutkind, J.S. and Pierce, JJ-l. (1992) EMBO J. 11, 4899-4908. 
[14] Wang, L.M., Keegan, Li, W,, Lienhard, G.E., Pacini, S., Gutkind, 
LS., Myers, M,G,, Sun, X.J,, White, ME, Aaronson, S,A., Paul, 
W.E. and Pierce, J.H. (1993) Proc. Natl. Acad. Sci. USA 90, 
4032--4036. 
[15] Keller, S.R. and Lienhard, G.E. (1994) Trends Cell Biol. 4, 115- 
119. 
[16] Kolher, I., Alliger, P., Minty, A., Caput, D., Ferrara, P., HoU- 
Neugebauer, B. Rank, G. and Rieber, E.P. (1994) FEBS Lett. 345, 
187-192. 
[17] Smers-lkrtling, C. and Duschl, A. (1995) J. Biol. Chem. 270, 
966-970. 
[18] Johnston, J.A., Kawamura, M,, Kirken, R.A., Chen, Y.Q., Blake, 
T.B., Shibuya, K., Ortaldo, J.R., McVicar, D.W. and O'Shea, J.J. 
(1994) Nature 370, 151-153. 
[19] Yin, T., Tsang, M.L.S. and Yang, Y.C. (1994) J. Biol. Chem. 269, 
26614-26617. 
[20] Matthews,D.J., Clark, P.A., Herbert, J , Morgan, G., Armitage, 
RJ., Kinnon, C., Minty, A., Grabstein, K.H., Caput, D., Ferrara, 
E and Callard, R. (1995) Blood 85, 38--42. 
